Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 35,353 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: NAFLD, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver, Fatty Liver
Interventions: Fibroscan screening; Other
Lead sponsor: Fatty liver Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Texas City, Texas

Conditions: Asthma
Interventions: 10 mg tablet of montelukast (Singulair); Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 7 Years to 35 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: PTSD, Post Traumatic Stress Disorder
Interventions: Cognitive Processing Therapy; Behavioral
Lead sponsor: VA Boston Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Fort Belvoir, Virginia

Conditions: Infections, Bacterial
Interventions: Gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: La Mesa, California

Conditions: Healthy Participants
Interventions: Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Hepatic Impairment
Interventions: KD025; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Rialto, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: LAD1
Interventions: Ustekinumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Peripheral Artery Disease
Interventions: FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB; Combination Product
Lead sponsor: VentureMed Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Inflammatory Bowel Diseases, Anxiety, Depression, Ulcerative Colitis, Crohn Disease
Interventions: Mental health support session; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital
Interventions: EDIT-101; Drug
Lead sponsor: Editas Medicine, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Heart Failure, Congestive
Interventions: GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Head and Neck Cancer
Interventions: [F-18] HX4; Radiation
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
Interventions: Axatilimab, Durvalumab; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • Baltimore, Maryland • Portland, Oregon + 1 more

Conditions: Primary Immune Deficiency
Interventions: Newnorm; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Irvine, California • Centennial, Colorado • Port Saint Lucie, Florida + 7 more

Conditions: Secondary Hyperparathyroidism
Interventions: Sensipar (Cinacalcet HCl); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more

Conditions: Healthy Adult Participants
Interventions: BGB-43395, Midazolam, Celecoxib, Dabigatran etexilate, Rosuvastatin; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
Interventions: Rapidly generated virus specific T (R-MVST) cells; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Acute Respiratory Infection, Influenza-like Illness
Interventions: Educational text messages; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 1,918 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: AV650, Fluvoxamine, Paroxetine; Drug
Lead sponsor: Avigen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Ovarian Neoplasms
Interventions: Avastin; Drug
Lead sponsor: Gynecologic Oncology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 2
States / cities: Newport Beach, California • Orlando, Florida

Conditions: Septic Shock
Interventions: Plasma, Balanced crystalloids; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatic Impairment
Interventions: Enasidenib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Conditions: Dental Fear, Anesthesia, Local, Pediatric Dentistry
Interventions: Synapse TENS device, Topical anesthetic gel; Device · Drug
Lead sponsor: Boston University; Other
Eligibility: 6 Years to 14 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions: Tiotropium; Drug
Lead sponsor: ThomasTruncale; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Tampa, Florida

Search by objective public record fields.

A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations

Genotype Stratified Pharmacokinetic Study of Montelukast

Massed Cognitive Processing Therapy for Combat-related PTSD

Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Prospective Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral And/or Popliteal Arteries Using the FLEX Scoring Catheter Plus DCB

Digital Support for Mental Health Intervention in Patients With Inflammatory Bowel Disease

Single Ascending Dose Study in Participants With LCA10

A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets

A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395

R-MVST Cells for Treatment of Viral Infections

FluSAFE: Flu SMS Alerts to Freeze Exposure

AV650 Drug-Drug Interaction Study

Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients

Resuscitation With Plasma in Surgical and Trauma Patients With Septic Shock

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Effectiveness of Synapse Transcutaneous Electronic Nerve Stimulation (TENS) During Dental Procedures Among Children

The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)